Q-omics provides the consensus-scored STAB2 profile across patient tissues and cancer cell-line models. STAB2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STAB2 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, STAB2 RNA expression shows 15,767 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where STAB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAB2 survival associations across molecular data types. STAB2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAB2 RNA expression–survival associations across cancer types. High STAB2 expression shows unfavorable associations in UVM, ACC and KIRP, but favorable associations in SCLC, BRCA and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STAB2 RNA expression.
This table summarizes STAB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STAB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAB2 shows lower tumor expression in THCA, COAD, BLCA, LIHC, BRCA and UCEC. The THCA box plot shows higher STAB2 RNA expression in normal versus tumor tissue (log2 FC = −1.129, t-test p < 0.001).
This table shows molecular features associated with STAB2 in patient tissues and cancer cell lines. In patient samples, STAB2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STAB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
